Stockscreener 앱 받기
2.535
10.42%
-0.295
시간 외 거래:
2.51
-0.025
-0.99%
C 4 Therapeutics Inc 주식(CCCC)의 최신 뉴스
Vera Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Analysts see significant upside in C4 Therapeutics (CCCC) stock - MSN
C4 Therapeutics Amends By-laws to Designate Federal Courts as Exclusive Forum for Securities Act Claims - Minichart
C4 Therapeutics updates bylaws to designate federal courts as exclusive forums - Investing.com
C4 Therapeutics (NASDAQ: CCCC) narrows forums for securities lawsuits - Stock Titan
C4 yourself: $1B second Roche deal evidence of DAC faith - BioWorld News
What's Going On With C4 Therapeutics Stock Thursday?C4 Therapeutics (NASDAQ:CCCC) - Benzinga
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates - Investing News Network
C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion - Reuters
C4 Therapeutics inks new deal with Roche (CCCC:NASDAQ) - Seeking Alpha
C4 Therapeutics and Roche Sign Over $1 Billion Collaboration to Develop Degrader-Antibody Conjugates for Cancer Treatment - Minichart
C4 Therapeutics Expands Roche Collaboration with New DAC Deal - TipRanks
C4 Therapeutics, Roche partner on cancer degrader conjugates - Investing.com
C4 Therapeutics (NASDAQ: CCCC) inks $1B+ DAC cancer deal with Roche - Stock Titan
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs) - The Manila Times
Roche expands C4T deal on a new cancer-drug approach worth $1B-plus - Stock Titan
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - marketscreener.com
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Director at C4 Therapeutics (NASDAQ: CCCC) granted 4,259 shares - Stock Titan
Director at C4 Therapeutics (NASDAQ: CCCC) takes stock pay - Stock Titan
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
New Bicara hire gets stock option for 44,175 shares at $20.50 - Stock Titan
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Candel Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Akebia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Fate Therapeutics reports new employee inducement award under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - bitget.com
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - globenewswire.com
CCCC Stock Price, Quote & Chart | C4 THERAPEUTICS INC (NASDAQ:CCCC) - ChartMill
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Is C4 Therapeutics (CCCC) stock outpacing its medical peers this year? - MSN
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update - MarketBeat
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year? - finance.yahoo.com
C4 Therapeutics, Inc. advances pipeline as SVP Shagha Russell drives cemsidomide toward regulatory studies - Traders Union
C4 Therapeutics begins trial of cemsidomide with elranatamab By Investing.com - Investing.com India
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab for Relapsed/Refractory Multiple Myeloma - Investing News Network
C4 Therapeutics begins trial of cemsidomide with elranatamab - Investing.com
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma - The Manila Times
C4 Therapeutics Announces First Patient Dosed in Phase 1b - GlobeNewswire
0.95%
3.83%
자본화:
|
볼륨(24시간):